David A. Siegel Uni Qure N.V. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Uni Qure N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 289,500 shares of QURE stock, worth $1.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
289,500
Previous 28,300
922.97%
Holding current value
$1.3 Million
Previous $191,000
687.96%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding QURE
# of Institutions
148Shares Held
34.1MCall Options Held
1.07MPut Options Held
603K-
Vestal Point Capital, LP New York, NY4.73MShares$21.2 Million2.03% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.09MShares$13.8 Million1.03% of portfolio
-
683 Capital Management, LLC New York, NY1.98MShares$8.85 Million0.88% of portfolio
-
Black Rock Inc. New York, NY1.86MShares$8.34 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.52MShares$6.8 Million0.0% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $209M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...